Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 4, 2006, Pages 436-440

  Tubbs, Raymond R ^a   Pettay, James D ^a   Swain, Eric ^a   Roche, Patrick C ^b   Powell, William ^b   Hicks, David G ^a   Grogan, Thomas ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Fluorescence in situ hybridization; Her 2 neu; HER2

Indexed keywords

ARTICLE; AUTOMATION; BREAST CARCINOMA; CONTROLLED STUDY; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIORITY JOURNAL; QUALITY CONTROL; TISSUE MICROARRAY; VALIDATION PROCESS;

AUTOMATION; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEASIBILITY STUDIES; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; SIGNAL PROCESSING, COMPUTER-ASSISTED; TISSUE ARRAY ANALYSIS;

EID: 33751382730     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213101.26193.f1     Document Type: Article

References (11)

1. Mina L, Sledge GW. Twenty years of systemic therapy for breast cancer. Oncology. 2006;20:25-32.
2. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001;28(1 Suppl 3): 13-19.
3. Mass R, Press M, Anderson S. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) (abstract #85). Presented at the American Society of Clinical Oncology, 2001.
4. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
5. Vogel C, Cobleigh M, Tripathy R. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients (abstract #86). Presented at the American Society of Clinical Oncology, 2001.
6. Bankfalvi A, Boecker W, Reiner A. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests. Int J Oncol. 2004;25:929-935.
7. Ellis CM, Dyson MJ, Stephenson TJ, et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005;58:710-714.
8. Klijanienko J, Couturier J, Galut M, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer. 1999;87:312-318.
9. Luftner D, Henschke P, Kafka A, et al. Discordant results obtained for different methods of HER-2/neu testing in breast cancer - a question of standardization, automation and timing. Int J Biol Markers. 2004;19:1-13.
10. Raimondo F, Gavrielides MA, Karayannopoulou G, et al. Automated evaluation of Her-2/neu status in breast tissue from fluorescent in situ hybridization images. IEEE Trans Image Process. 2005;14:1288-1299.
11. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495-503.